Early Parkinson's Drug Hits Targets in Phase III Studies

(MedPage Today) — SAN DIEGO — Both fixed and flexible doses of investigational tavapadon met their primary endpoint in phase III trials of early Parkinson’s disease.
In the TEMPO-1 (fixed dose) and TEMPO-2 (flexible dose) studies, participants…